Aerocrine Announces Presentation of Data on FeNO Testing in Overlap Syndrome at American Thoracic Society 2013
Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!
Aerocrine AB (OMX Nordic Exchange: AERO) ---Aerocrine, Inc. today announced the following scientific abstract, Characterization of Allergic Airway Inflammation in Patients with COPD using Fractional exhaled Nitric Oxide Level (FeNO)s, presented at the 2013 American Thoracic Society International Conference. The abstract was presented by Dr. James F. Donohue, principle investigator for the study at (American Thoracic Society meeting in Philadelphia) on (Sunday May 19, 2013).
Help employers find you! Check out all the jobs and post your resume.
Aerocrine AB (OMX Nordic Exchange: AERO) ---Aerocrine, Inc. today announced the following scientific abstract, Characterization of Allergic Airway Inflammation in Patients with COPD using Fractional exhaled Nitric Oxide Level (FeNO)s, presented at the 2013 American Thoracic Society International Conference. The abstract was presented by Dr. James F. Donohue, principle investigator for the study at (American Thoracic Society meeting in Philadelphia) on (Sunday May 19, 2013).
Help employers find you! Check out all the jobs and post your resume.